Nucleic acid probe set and nucleic acid lateral flow immunoassay having the same
A nucleic acid probe set is disclosed. The nucleic acid probe set comprises a detection probe and a capture probe, and the detection probe and the capture probe both include a nucleotide sequence that is extracted from a conserved region of a genome sequence belong to a BK virus. A nucleic acid lateral flow immunoassay for using in detection of BK virus is also disclosed. The nucleic acid lateral flow immunoassay comprises: the forgoing nucleic acid probe set, a test strip, and a streptavidin (SA) solution. Experimental data have proved that, the nucleic acid lateral flow immunoassay can be adopted for conducting a BK virus detection on a sample that is collected from environmental water, sewage water, drinking water, urine, or serum.
1. A nucleic acid probe set, comprising:
a capture probe, comprising a first nucleotide sequence that comprises at least 19 nucleotide bases and a combiner connected to one terminal base of the first nucleotide sequence; and
a detection probe, comprising a second nucleotide sequence that comprises at least 19 nucleotide bases and a label connected to one terminal base of the second nucleotide sequence;
wherein the first nucleotide sequence and the second nucleotide sequence
comprise a nucleotide sequence of 5′-GAAAGGAAGGTAAGTTGTTAAG-3′ (SEQ ID NO:8) and 5′-TATGTATGAATAGAGTCTTAGGT-3′ (SEQ ID NO:7), respectively, or vice versa.
2. The nucleic acid probe set of claim 1 , wherein the combiner is a biotin that is used to combine with a streptavidin (SA), and the label being made of a fluorescent material that is selected from a group consisting of gold nanoparticles, silver nanoparticles, carbon nanoparticles, quantum dots (QDs), colloidal gold, colloidal silver, and colloidal QDs.
3. The nucleic acid probe set of claim 1 , wherein the terminal base of the first nucleotide sequence connected with the combiner is a 5′-terminal base or a 3′-terminal base, the terminal base of the second nucleotide sequence connected with the label is a 5′-terminal base or a 3′-terminal base.
4. The nucleic acid probe set of claim 1 , wherein the capture probe further comprises a spacer that is connected between the terminal base and the combiner, and the spacer comprises 10 adenines.
5. The nucleic acid probe set of claim 1 , wherein the detection probe further comprises a spacer connected to the terminal base and a thiol group connected between the spacer and the label, and the spacer comprises 10 adenines.
6. The nucleic acid probe set of claim 1 , wherein the label is made of gold nanoparticles having a particle size in a range between 25 nm and 65 nm.
7. A nucleic acid lateral flow immunoassay for detecting BK virus, comprising: a lateral flow strip and a tetrameric protein solution for solving a sample; characterised in that the nucleic acid lateral flow immunoassay further comprising:
a capture probe for being mixed in a test solution consisting of the tetrameric protein solution and the sample, comprising a first nucleotide sequence that comprises at least 19 nucleotide bases and a combiner connected to one terminal base of the first nucleotide sequence; and
a detection probe for being mixed in a test sample, comprising a second nucleotide sequence that comprises at least 19 nucleotide bases and a label connected to one terminal base of the second nucleotide sequence; wherein the first nucleotide sequence and the second nucleotide sequence comprise a nucleotide sequence of 5′ GAAAGGAAGGTAAGTTGTTAAG-3′ (SEQ ID NO:8) and 5′-TATGTATGAATAGAGTCTTAGGT-3′ (SEQ ID NO:7), respectively, or vice versa.
8. The nucleic acid lateral flow immunoassay of claim 7 , wherein the tetrameric protein solution comprising a buffer liquid and a tetrameric protein dissolved or dispersed in the buffer liquid.
9. The nucleic acid lateral flow immunoassay of claim 8 , wherein the tetrameric protein is a streptavidin (SA), and the buffer liquid is a phosphate buffer solution.
10. The nucleic acid lateral flow immunoassay of claim 7 , wherein the lateral flow strip further comprises:
a supporting substrate, wherein a membrane substrate is disposed on the supporting substrate; and
an absorption pad, being formed on the supporting substrate, and being located at a rear-end side of the supporting substrate.
11. The nucleic acid lateral flow immunoassay of claim 10 , wherein the membrane substrate is made of a material that is selected from a group consisting of nitrocellulose (NC), polyvinylidene difluoride (PVDF) and nylon.
12. The nucleic acid lateral flow immunoassay of claim 7 , wherein the combiner is a biotin, and the label is made of a fluorescent material that is selected from a group consisting of gold nanoparticles, silver nanoparticles, carbon nanoparticles, quantum dots (QDs), colloidal gold, colloidal silver, and colloidal QDs.
13. The nucleic acid lateral flow immunoassay of claim 7 , wherein the terminal base of the first nucleotide sequence connected with the combiner is a 5′-terminal base or a 3′-terminal base, the terminal base of the second nucleotide sequence connected with the label is a 5′-terminal base or a 3′-terminal base.
14. The nucleic acid lateral flow immunoassay of claim 7 , wherein the capture probe further comprises a spacer that is connected between the terminal base and the combiner, and the spacer comprises adenines.
15. The nucleic acid lateral flow immunoassay of claim 7 , wherein the detection probe further comprises a spacer connected to the terminal base and a thiol group connected between the spacer and the label, and the spacer comprises adenines.